top of page
Learn how FutureMeds increases patient access to oncology trials
What's inside
What you will learn
Why traditional, hospital-centric trials are falling short — and what’s holding back participation
The 3 key barriers to patient enrolment and how to overcome them
Real-world case study from FutureMeds’ research clinics
How decentralized clinical trial (DCT) elements can improve patient access, convenience, and outcomes
How FutureMeds’ model supports faster recruitment, better retention, and consistent quality
The Problem
The Industry Face
Despite medical innovation, trial participation has stagnated. Hospitals remain overburdened, physicians are wary, and many patients never learn that trials are even an option.
Only 2–8% of cancer patients participate in trials
Many live too far from a trial site or lack the resources to attend
Bringing Trials
Into the Community
FutureMeds is leading the shift from hospital-centered trials to community-based, patient-centric research supported by DCT solutions.
Increase trial access and awareness in underserved communities
Support physicians with specialist research staff and centralised support
"We believe meaningful progress in oncology trials comes from working together with patients, clinicians, the wider community and sponsors. Our community-based patient engagement model is designed to remove the traditional barriers to oncology trials, expanding access and accelerating results."
Dr Piotr Rozpondek
Managing Director,
FutureMeds Poland
.png)
bottom of page